Translational Toxicology and Therapeutics E-Book

• Herausgeber: John Wiley & Sons
• Kategorie: Fachliteratur
• Sprache: Englisch

Seitenzahl: 1528

Veröffentlichungsjahr: 2017

Beschreibung

Written by leading research scientists, this book integrates current knowledge of toxicology and human health through coverage of environmental toxicants, genetic / epigenetic mechanisms, and carcinogenicity. * Provides information on lifestyle choices that can reduce cancer risk * Offers a systematic approach to identify mutagenic, developmental and reproductive toxicants * Helps readers develop new animal models and tests to assess toxic impacts of mutation and cancer on human health * Explains specific cellular and molecular targets of known toxicants operating through genetic and epigenetic mechanisms

Leseprobe

CONTENTS

Cover

Title Page

Copyright

List of Contributors

Part One: Introduction: The Case for Concern about Mutation and Cancer Susceptibility during Critical Windows of Development and the Opportunity to Translate Toxicology into a Therapeutic Discipline

Chapter 1: What Stressors Cause Cancer and When?

1.1 Introduction

1.2 What Stressors Cause Cancer and When?

1.3 Relevance of Circulating Cancer Markers

1.4 Potential Cancer Translational Toxicology Therapies

1.5 Modeling and the Future

References

Chapter 2: What Mutagenic Events Contribute to Human Cancer and Genetic Disease?

2.1 Introduction

2.2 Genetic Damage from Environmental Agents

2.3 Testing for Mutagenicity and Carcinogenicity

2.4 Predictive Toxicogenomics for Carcinogenicity

2.5 Germ Line Mutagenicity and Screening Tests

2.6 Reproductive Toxicology Assays in the Assessment of Heritable Effects

2.7 Assays in Need of Further Development or Validation

2.8 New Technologies

2.9 Endpoints Most Relevant to Human Genetic Risk

2.10 Worldwide Regulatory Requirements for Germ Cell Testing

2.11 Conclusion

Acknowledgments

References

Chapter 3: Developmental Origins of Cancer

3.1 Introduction

3.2 Current Trends in Childhood Cancer

3.3 Potential Mechanisms of Prenatal Cancer Induction

3.4 Ontogeny of Xenobiotic Metabolizing Enzymes and DNA Repair Systems

3.5 The Developmental Origins of Health and Disease (DOHaD) Theory

3.6 Epigenetic Regulation during Development

3.7 Mechanisms of Cancer in Offspring from Paternal Exposures

3.8 Parental Exposures Associated with Cancer in Offspring

3.9 Models for the Developmental Origins of Selected Cancers

3.10 Public Health Agencies' Views on Prenatal Exposures and Cancer Risk

3.11 Conclusions

Acknowledgment

References

Chapter 4: The Mechanistic Basis of Cancer Prevention

4.1 Introduction

4.2 A Mechanistic Approach

4.3 Preventing Cancer Attributable to Known Carcinogens

4.4 Prevention Involving Complex Risk Factors

4.5 Prevention Independent of Causative Agents or Risk Factors

4.6 Conclusion

References

Part Two: Exposures that Could Alter the Risk of Cancer Occurrence, and Impact Its Indolent or Aggressive Behavior and Progression Over Time

Chapter 5: Diet Factors in Cancer Risk

5.1 Introduction

5.2 Obesity

5.3 Macronutrients

5.4 Micronutrients

5.5 Phytochemicals

5.6 Conclusions

References

Chapter 6: Voluntary Exposures: Natural Herbals, Supplements, and Substances of Abuse – What Evidence Distinguishes Therapeutic from Adverse Responses?

6.1 Introduction

6.2 Summary and Conclusions

References

Chapter 7: Voluntary Exposures: Pharmaceutical Chemicals in Prescription and Over-the-Counter Drugs – Passing the Testing Gauntlet

7.1 Introduction

7.2 Testing of New Drug Entities for Genotoxicity

7.3 Relationship between Genotoxicity Testing and Rodent Carcinogenicity

7.4 Can Drug-Induced Human Cancer Be Predicted?

7.5 What Can Rodent Carcinogenicity Tell Us about Human Cancer Risk?

7.6 Genotoxicity Prediction Using “Traditional” In Silico Approaches

7.7 Covalent versus Noncovalent DNA Interaction

7.8 Use of New Technologies to Predict Toxicity and Cancer Risk: High-Throughput Methods

7.9 Transcriptomics

7.10 Single-Nucleotide Polymorphisms (SNPs)

7.11 Conclusions

Appendix A

References

Chapter 8: Children's and Adult Involuntary and Occupational Exposures and Cancer

8.1 Introduction

8.2 Occupational Exposures and Cancer

8.3 Environmental Exposures and Cancer

8.4 Conclusions and Future Perspectives

References

Part Three: Gene–Environment Interactions

Chapter 9: Ethnicity, Geographic Location, and Cancer

9.1 Introduction

9.2 Classification of Cancer

9.3 Ethnicity and Cancer

9.4 Geographic Location and Cancer

9.5 Ethnicity, Geographic Location, and Lung Cancer

9.6 Common Cancers in China

9.7 Cancer Risk Factors and Prevention

References

Chapter 10: Dietary/Supplemental Interventions and Personal Dietary Preferences for Cancer: Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction

10.1 Introduction

10.2 Gene Expression and Epigenetics

10.3 Environmental Lifestyle Factors Affecting Cancer Prevention and Risk

10.4 Dietary Patterns

10.5 Complementary and Integrative Oncology Interventions/Restorative Therapeutics

10.6 Special and Alternative Diets

10.7 Popular Anticancer Diets

10.8 Conclusion

Acknowledgment

References

Chapter 11: Social Determinants of Health and the Environmental Exposures: A Promising Partnership

11.1 Introduction

11.2 Social Determinants of Health

11.3 Conclusions: Social Determinants of Health and Windows of Susceptibility

Acknowledgments

References

Part Four: Categorical and Pleiotropic Nonmutagenic Modes of Action of Toxicants: Causality

Chapter 12: Bisphenol A and Nongenotoxic Drivers of Cancer

12.1 Introduction

12.2 Dosing

12.3 Receptor-mediated Signaling

12.4 Epigenetic Reprogramming

12.5 Oxidative Stress

12.6 Inflammation and Immune Response

12.7 BPA-Induced Carcinogenesis

12.8 Fresh Opportunities in BPA Research

References

Chapter 13: Toxicoepigenetics and Effects on Life Course Disease Susceptibility

13.1 Introduction to the Field of Toxicoepigenetics

13.2 Exposures that Influence the Epigenome

13.3 Intergenerational Exposures and Epigenetic Effects

13.4 Special Considerations and Future Directions for the Field of Toxicoepigenetics

13.5 Future Directions

13.6 Conclusions

Acknowledgments

References

Chapter 14: Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons

14.1 Introduction

14.2 The Immune System

14.3 Prioritized Chemicals

14.4 Experimental Models of Carcinogenesis through Inflammation and Immune System Deregulation

14.5 Antioxidants and Translational Opportunities

14.6 Tumor Control of the Microenvironment

Acknowledgments

References

Chapter 15: Metabolic Dysregulation in Environmental Carcinogenesis and Toxicology

15.1 Introduction

15.2 Metabolic Reprogramming and Dysregulation in Cancer

15.3 Moonlighting Functions

15.4 Cancer Metabolism in Context

15.5 Dual Roles for Metabolism in Both the Generation and Mitigation of Cellular Stress

15.6 Models of Carcinogenesis

15.7 Potential Metabolic Targets for Environmental Exposures

15.8 Metabolic Changes Associated with Exposures to Selected Agents

15.9 A Conceptual Overview of Traditional and Emerging Toxicological Approaches to the Problem of Cancer Metabolism: Implications for Future Research

15.10 The Nosology of Cancer and Cancer Development

15.11 Discussion

Acknowledgments

References

Part Five: Biomarkers for Detecting Premalignant Effects and Responses to Protective Therapies during Critical Windows of Development

Chapter 16: Circulating Molecular and Cellular Biomarkers in Cancer

16.1 Introduction

16.2 Proteins in Body Fluids: Potential Biomarkers

16.3 Circulating Cell-Free Nucleic Acids

16.4 Extracellular Vesicles: General Features

16.5 Circulating Tumor Cells

16.6 Conclusions

References

Chapter 17: Global Profiling Platforms and Data Integration to Inform Systems Biology and Translational Toxicology

17.1 Introduction

17.2 Global Omics Profiling Platforms

17.3 High-Throughput Bioactivity Profiling

17.4 Biomarkers

17.5 Exposomics

17.6 Bioinformatics to Support and Data Integration and Multiomics Efforts

17.7 Data Integration: Multiomics and High-Dimensional Biology Efforts

17.8 Conclusion

References

Chapter 18: Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction

18.1 Introduction

18.2 The Identification of Novel Predictors of Adverse Events

18.3 Proof of Principle Toxgnostics

18.4 Proposed Protocol

18.5 Fiscal Matters

18.6 The Future of Toxgnostics

References

Chapter 19: Ethical Considerations in Developing Strategies for Protecting Fetuses, Neonates, Children, and Adolescents from Exposures to Hazardous Environmental Agents

19.1 Introduction

19.2 What Is Ethics?

19.3 Ethical Considerations for Strategies Used to Protect Fetuses, Neonates, Children, and Adolescents from Exposures to Harmful Environmental Agents

19.4 Research with Human Participants

19.5 Conclusion

References

Index

End User License Agreement

List of Tables

Table 1.1

Table 1.2

Table 2.1

Table 2.2

Table 2.3

Table 2.4

Table 2.5

Table 3.1

Table 3.2

Table 3.3

Table 7.1

Table 7.2

Table 8.1

Table 8.2

Table 9.1

Table 9.2

Table 9.3

Table 9.4

Table 9.5

Table 9.6

Table 10.1

Table 10.2

Table 12.1

Table 15.1

Table 17.1

Table 17.2

Table 18.1

Table 18.2

List of Illustrations

Figure 1.1

Figure 1.2

Figure 1.3

Figure 1.4

Figure 2.1

Figure 3.1

Figure 3.2

Figure 3.3

Figure 3.4

Figure 3.5

Figure 7.1

Figure 7.2

Figure 8.1

Figure 8.2

Figure 9.1

Figure 11.1

Figure 13.1

Figure 14.1

Figure 15.1

Figure 15.2

Figure 15.3

Figure 15.4

Figure 15.5

Figure 16.1

Figure 17.1

Figure 18.1

Guide

Cover

Table of Contents

Begin Reading

Part 1

Chapter 1

Pages

i

ii

ii

iii

xix

xx

xxi

xxii

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

Translational Toxicology and Therapeutics

Windows of Developmental Susceptibility in Reproduction and Cancer

Edited by

Michael D. Waters

Michael Waters Consulting USAHillsborough, NC, USA

Claude L. Hughes

Therapeutic Science and Strategy Unit QuintilesIMS Inc.Morrisville, NC, USA

Department of Obstetrics and GynecologyDuke University Medical CenterDurham, NC, USA

Department of Mathematics North Carolina State UniversityRaleigh, NC, USA

This edition first published 2018

© 2018 John Wiley & Sons, Inc

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.

The right of Michael D. Waters and Claude L. Hughes to be identified as the editors of this work has been asserted in accordance with law.

Registered Offices

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print on demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The publisher and the authors make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or website is referred to in this work as a citation and/or potential source of further information does not mean that the author or the publisher endorses the information the organization or website may provide or recommendations it may make. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this works was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging in Publication Data applied for.

Hardback ISBN: 9781119023609

Cover image: (Background) © portishead1/Gettyimages; (Top left, lower left and right side hexagon) © John Rensten/Gettyimages; © agsandrew/Gettyimages; © tashechka/Gettyimages

Cover design by Wiley

List of Contributors

Amedeo Amedei

Department of Experimental and Clinical Medicine

University of Florence

Firenze

Italy

David Berrigan

Division of Cancer Control and Population Sciences

National Cancer Institute

National Institutes of Health

Rockville, MD

USA

William H. Bisson

Knight Cancer Institute

Oregon Health & Science University

Portland, OR

USA

Ilaria Chiodi

Institute of Molecular Genetics

Pavia

Italy

Annamaria Colacci

Center for Environmental Toxicology and Risk Assessment

Regional Agency for Prevention

Environment and Energy

Emilia Romagna Region

Italy

Eli P. Crapper

Department of Obstetrics & Gynaecology

McMaster University

Hamilton

Ontario

Canada

Dana C. Dolinoy

Department of Environmental Health Sciences

University of Michigan School of Public Health

Ann Arbor, MI

USA

Department of Nutritional Sciences

University of Michigan School of Public Health, Ann Arbor, MI

USA

Dean W. Felsher

Division of Oncology

Departments of Medicine and Pathology

Stanford University School of Medicine

Stanford, CA

USA

Lynnette R. Ferguson

Discipline of Nutrition and Dietetics and Auckland Cancer Society Research Centre

Faculty of Medical and Health Sciences

The University of Auckland

Auckland

New Zealand

Lauren Fordyce

Office of Behavioral and Social Sciences Research

Office of the Director

National Institutes of Health

Bethesda, MD

USA

Stefano Forte

Department of Experimental Oncology

Mediterranean Institute of Oncology

Viagrande (CT)

Italy

Katelyn J. Foster

Department of Obstetrics & Gynaecology

McMaster University

Hamilton

Ontario

Canada

Warren G. Foster

Department of Obstetrics & Gynaecology

McMaster University

Hamilton

Ontario

Canada

Department of Reproductive Medicine

University of California San Diego

San Diego, CA

USA

Natalie R. Gassman

Department of Oncologic Sciences

University of South Alabama Mitchell Cancer Institute

Mobile, AL

USA

Jaclyn M. Goodrich

Department of Environmental Health Sciences, University of Michigan School of Public

Health, Ann Arbor, MI

USA

Claude L. Hughes

Therapeutic Science and Strategy Unit

QuintilesIMS Inc.

Morrisville, NC

USA

Department of Obstetrics and Gynecology

Duke University Medical Center

Durham, NC

USA

Department of Mathematics

North Carolina State University

Raleigh, NC

USA

Rebecca Johnson

Nuffield Division of Clinical Laboratory Sciences

Radcliffe Department of Medicine

University of Oxford

John Radcliffe Infirmary

Headington

Oxford

UK

Sandeep Kaur

Nutritional Science Research Group

Division of Cancer Prevention

National Cancer Institute

National Institutes of Health

Rockville, MD

USA

David Kerr

Nuffield Division of Clinical Laboratory Sciences

Radcliffe Department of Medicine

University of Oxford

John Radcliffe Infirmary

Headington

Oxford

UK

Lorenzo Memeo

Department of Experimental Oncology

Mediterranean Institute of Oncology

Viagrande (CT)

Italy

Melissa J. Mills

Mills Consulting

LLC

Durham, NC

USA

Chiara Mondello

Institute of Molecular Genetics

Pavia

Italy

Luke Montrose

Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI

USA

David B. Resnik

National Institute of Environmental Health Sciences (NIEHS)

Research Triangle Park, NC

USA

R. Brooks Robey

White River Junction Veterans Affairs Medical Center

White River Junction, VT

USA

Geisel School of Medicine at Dartmouth

Hanover, NH

USA

John M. Rogers

Toxicity Assessment Division

National Health and Environmental Effects Research Laboratory

Office of Research and Development

United States Environmental Protection Agency

Research Triangle Park, NC

USA

A. Ivana Scovassi

Institute of Molecular Genetics

Pavia

Italy

Harold Seifried

Nutritional Science Research Group

Division of Cancer Prevention

National Cancer Institute

National Institutes of Health

Rockville, MD

USA

Ronald D. Snyder

RDS Consulting Services

Mason, OH

USA

Shobha Srinivasan

Division of Cancer Control and Population Sciences

National Cancer Institute

National Institutes of Health

Rockville, MD

USA

Bernard W. Stewart

Cancer Control Program

South Eastern Sydney Public Health Unit and Faculty of Medicine

University of New South Wales

Sydney

Australia

Elaine Trujillo

Nutritional Science Research Group

Division of Cancer Prevention

National Cancer Institute

National Institutes of Health

Rockville, MD

USA

Monica Vaccari

Center for Environmental Toxicology and Risk Assessment

Regional Agency for Prevention

Environment and Energy

Emilia Romagna Region

Italy

Suryanarayana V. Vulimiri

National Center for Environmental Assessment

Office of Research and Development

United States Environmental Protection Agency

Washington, DC

USA

Kylie Wasser

Department of Human Kinetics

Western University

London

Ontario

Canada

Michael D. Waters

Michael Waters Consulting USA

Hillsborough, NC

USA

Barbara A. Wetmore

Office of Research and Development

U.S. Environmental Protection Agency

Research Triangle Park, NC

USA

Samuel H. Wilson

Genome Integrity and Structural Biology Laboratory

National Institute of Environmental Health Sciences (NIEHS)

Research Triangle Park, NC

USA

Fengyu Zhang

Global Clinical and Translational Research Institute

Bethesda, MD

USA

Part OneIntroduction: The Case for Concern about Mutation and Cancer Susceptibility during Critical Windows of Development and the Opportunity to Translate Toxicology into a Therapeutic Discipline

1What Stressors Cause Cancer and When?

Claude L. Hughes1,2,3 and Michael D. Waters4

1Therapeutic Science and Strategy Unit QuintilesIMS Inc., Morrisville, NC, USA

2Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA

3Department of Mathematics, North Carolina State University, Raleigh, NC, USA

4Michael Waters Consulting USA, Hillsborough, NC, USA

1.1 Introduction

Translational biomedical research seeks to move laboratory findings based on models (in silico, in vitro, and in vivo) into human clinical trials to more expeditiously develop specific therapeutics, and then back again to the laboratory to inform future discovery [1]. From the background of developmental toxicology, it is well known that toxicant exposures may affect critical events in reproductive development, ranging from early primordial germ cell determination to gonadal differentiation, gametogenesis, external genitalia, or signaling events regulating sexual behavior. Translational genetic toxicology takes advantage of this developmental perspective to assess potential germ line mutagenesis or to study the potential for cancer in the fetus or offspring or the adult as the result of environmental exposures. Translational toxicology must strive to identify applicable therapeutics that can safely and effectively identify and help to mitigate potential harm from natural as well as anthropogenic environmental exposures.

Human exposures to chemicals, physical agents, and social factors are inevitable, thus the human fetus and the adult are subject to exposures and effects that can have lifelong consequences. Particularly, during dynamic developmental intervals described as “critical windows of susceptibility,” exposures may have robust and durable effects that drive long-term health outcomes, including metabolism, functional status of organ systems, and cancer risks [2]. These same dynamic developmental intervals should be seen as “critical windows of responsivity” during which favorable/protective interventions should also be highly impactful offering potential durable reduction in risks of multiple adverse health outcomes, including cancers. To reduce the lifelong occurrence of preventable cancers, timely protective interventions during “critical windows” should include not only minimization of untoward voluntary exposures and substances of abuse but also active use of protective generally recognized as safe (GRAS) interventions/therapies, including nutritional, dietary supplementation, or well-established/repurposed and/or generally recognized as safe and effective (GRASE) pharmaceutical drugs.

This introductory chapter will promote the elucidation of cell stage, life stage, and lifestyle knowledge of specific cellular and molecular targets of known developmental toxicants, develop a systematic integrated approach to the identification of mutagenic and reproductive toxicants, and discuss sensitive, specific, and predictive animal models, to include minimally invasive surrogate markers, and/or in vitro tests to assess reproductive system function during embryonic, postnatal, and adult life. It will argue that integrated testing strategies will be required to account for the many mechanisms associated with development that occur in vivo. A key organizing principle used throughout this book is to consider how exposures that incur risk or other exposures/life events that may reduce risk during particular windows of susceptibility/developmental transitions, and thereby impact cancer occurrence.

In consideration of any cause–effect relationship, typically one thinks of the simple questions: Who, what, where, when, and how? Admittedly, “How?” questions are generally the most difficult because that understanding is a synthesis of potentially causal pathways. We aim to consider that the “Who?” and “When?” questions could be seen as people being exposed at different intervals across their respective life spans. Thus, in addition to information regarding what exposures occur that influence cancer occurrence, what is and is not known about exposures to those agents during life span intervals such as childhood, adolescence, across the broader life span, and/or late in life? Assessment of such timing of exposure with cancer outcomes seems to be a critical element if we aim to develop protective interventional strategies. In other words, whether we aim to reduce exposures or advocate protective lifestyle or therapeutic interventions, we must know when those interventions would most effectively impact later cancer outcomes.

Although there are differences between human development and that of laboratory animal models, developmental models have been extremely useful in assessing risks for key human reproductive and developmental processes. Some of these models will be discussed in Chapters 2 and 3. However, such systems have not been fully integrated with models to assess germ line mutagenesis or to study the potential for cancer in the fetus or offspring as the result of environmental exposures. Again, Chapters 2 and 3 will address current proposals for experimental animal test system integration.

To delve into the impact of exposures during “windows of susceptibility/responsivity,” we must take into account the unique susceptibilities of the fetus. Relatively, new information suggests that some widely held notions relevant to fetal exposures are incorrect [3]. Thus, we now know that amniotic fluid can be reabsorbed into the fetal circulation by fetal swallowing as well as via the fetal intramembranous pathway. The latter pathway is thought to be the most important mechanism for the resorption of toxicants, such as ethanol, into the fetal circulation [4]. Together with swallowing, this is a recycling system, through which toxic substances are excreted into the amniotic fluid and reabsorbed into the fetal circulation, thus extending the duration of each exposure [5,6]. This and other information relevant to fetal exposure in utero will be discussed in Chapter 8.

1.1.1 General Information about Cancer

Each year the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States that year. In 2016, a total of 1,685,210 new cancer cases were expected to be diagnosed and about 595,690 cancer deaths were projected to occur in the United States [7]. Among children up to 14 years of age, an estimated 10,380 new cancer cases were expected to occur in 2016.

Population-based cancer registration began in the United States in 1975. Since then, childhood cancer incidence rates have increased by 0.6% per year. In 2016, 1250 cancer deaths were expected to occur among children. Cancer is the second leading cause of death in children ages 1–14 years, exceeded only by accidents. Childhood cancer death rates declined a total of 66% from 1969 (6.5 per 100,000) to 2012 (2.2 per 100,000). According to the American Society, this was largely due to improvements in treatment and high rates of participation in clinical trials. From 2003 to 2012, the rate of cancer-caused deaths in children declined by 1.3% per year.

Siegel et al. [8] reported that during the period 2006–2010, the then most recent 5 years for which there were data, the delay-adjusted cancer incidence rates declined by 0.6% per year in men and were stable in women. At the same time, cancer death rates decreased by 1.8% per year in men and by 1.4% per year in women. The rate of combined cancer deaths per 100,000 populations has declined continuously for two decades, from a peak of 215.1 in 1991 to 171.8 in 2010. The 20% decline during this time period equates to the avoidance of 1,340,400 cancer deaths (952,700 among men and 387,700 among women). Siegel et al. reported that the magnitude of the decline in cancer death rates varies substantially by age, race, and sex, with no decline among white women of 80 years of age and older to a 55% decline among black men 40–49 years of age. Remarkably, black men experienced the largest drop within every 10-year age group. The authors noted that progress could be accelerated by applying cancer control knowledge across all segments of the population [8].

While the severity of cancers is often measured in number of deaths, the number of years of life lost (YLL) may be a more appropriate indicator of impact on society [9]. These authors calculated the YLL of adult cancers in Norway for 2012 and for the prior 15-year period. Their results showed that cancer deaths in Norway in 2012 represented 25.8% of all adult deaths (28.7% in men and 23.1% in women). Cancer deaths represented 35.2% of all YLL, with a 5.0% higher fraction in females than in males (32.8% in men and 37.8% in women) [9].

The etiology of cancer is generally thought to be the product of gene and environmental interactions. Environmental exposures are typically low and to mixtures of constituents that occur indoors and outdoors. Goodson et al. hypothesized that low-dose exposures to mixtures of chemicals in the environment may be combining to contribute to environmental carcinogenesis [10]. They reviewed 11 hallmark phenotypes of cancer, with multiple priority target sites for disruption in each area and prototypical chemical disruptors for all targets. Dose–response characterizations and evidence of low-dose effects and cross-hallmark effects for all targets and chemicals were considered. In total, 85 examples of chemicals were reviewed for their actions on key pathways and mechanisms related to carcinogenesis. Although 59% of the chemicals caused low-dose effects, only 15% (13/85) were found to show evidence of a dose–response threshold. No dose–response information was found for the remaining 26% (22/85). The authors speculated that the cumulative effects of individual noncarcinogenic chemicals acting on different pathways in related systems, organs, tissues, and cells could synergize to produce carcinogenic outcomes. They concluded that additional research on carcinogenesis focused on low-dose effects of chemical mixtures needs to be rigorously pursued before the merits of their hypothesis can be further tested [10].

In a published poster abstract, Parkin and Paul [11] estimated the percentage of cancer in the United Kingdom in 2010 resulting from exposure to 14 major life style, dietary, and environmental risk factors. Prevalence and relative risks of exposure to factors, including tobacco smoking, consumption of four different dietary components (fruit and vegetables, meat, fiber, salt) alcohol use, occupation, infections, radiation, hormone use, overweight, physical exercise, and reproductive factors were used to estimate the number of cancers occurring in 2010 attributable to suboptimal exposure levels in the past. These 14 exposures were responsible for 42% of cancer in the United Kingdom in 2010 (males 44%, females 40%). Tobacco smoking was the most important, accounting for about 60,000 new cancers (18.5% of all cancer; 22% in men, 15% in women), with less than 2% being the result of exposure to environmental tobacco smoke. The four dietary components account for 9.4% of cancer (10.7% in men, 7.1% in women). In men, alcohol use (5.1%) and occupational exposures (4.7%) are next in importance and in women, overweight and obesity are next (nearly 7% of cancers). The study is cited because estimates of this kind provide a quantitative assessment of the impact of various exposures. However, they are not synonymous with the fraction of cancers that might reasonably be prevented by modification of exposures. As discussed by the authors, “this requires scenario modeling, with assumptions on a realistically achievable population distribution of risk factors, and the timescale of change.” For example, although 50% of colorectal cancer can be attributed to lifestyle (diet, alcohol, inactivity, and overweight), only about 25% is preventable within a 20-year timescale [11].

Langley et al. [12] proposed a new research paradigm, adapted from twenty-first century toxicology that involves the following initiatives:

Develop a “big picture” of human disease that integrates extrinsic and intrinsic causes and links environmental sciences with medical research using systems biology.

Introduce a disease-centric adverse outcome pathway (AOP) concept, analogous to toxicity AOPs, with the intention of providing a unified framework for describing relevant pathophysiology pathways and networks across multiple biological levels.

Create a strong focus on advanced human-specific research (

in vitro

,

ex vivo

,

in vivo

, and

in silico

) in lieu of empirical, animal-based studies.

Langley et al. [12] have asserted that integrating data on extrinsic and intrinsic causes of disease using a systems biology (or systems toxicology) approach provides a more comprehensive understanding of human illnesses. Such an approach involves the perturbation of a biological system and the use of molecular expression data gathered through the use of omics technologies to understand the responses that occur at the systems level [13–15].

The AOP concept links exposure, involving chemical structures and molecular initiating events, via a sequence of key events, to an adverse outcome [16]. In a genomic sense, AOPs link external influences (the exposome), including drugs, chemicals in consumer products, food, or the environmental media, occupational exposures, infections, behavior, stress, smoking, ageing, nutrition, and radiation exposure to genetic effects (the genome), including susceptibility genes, up- and downregulation of genes, germ line and somatic mutations induced by drugs, chemicals and/or radiation, inherited single nucleotide polymorphisms, gene copy number changes, insertions, deletions, exome changes, and the accumulation of DNA damage, as well as epigenetic effects (the epigenome), including changes in the localized or global density of DNA methylation; posttranslational modifications of histones; changes in noncoding microRNAs; and changes in chromatin structure, which together alter the regulation of gene expression. Defects in the epigenome can cause disease and may be specific to tissue or cell types. Both genetic and epigenetic effects are then linked to adverse effects at cellular, organ, and individual levels.

According to Langley et al., cellular/organ pathways may locate in immune function, apoptosis, calcium homeostasis, oxidative stress, growth factor signaling, nerve degeneration, and so on. Individual-level effects include embryonic development, disease, and death [12]. We certainly concur with this thinking and applaud the proposed new research paradigm, recognizing that systems biology and systems toxicology must ultimately be understood at the network level as will be further discussed in Section 1.5.

1.1.2 Stressors and Adaptive Responses

A general reality in biology is that living systems are inevitably subject to external stressors, and a general observation is that these complex biological systems respond by adaptation – if those stresses do not exceed some definable threshold. Such adaptation includes subsequent strengthening of various endogenous responses as well as development of more diversified responses. A semantic point may be made that there is a gradation of meaning where stressors might be seen as positive stimuli on one end of the scale, but potentially harmful or lethal insults on the other end of the scale. Exposures in the early life impact cancer risk across the life span, with some increasing that risk but others reducing it.

1.2 What Stressors Cause Cancer and When?

We must view this question at the cell level, the life stage, and from a lifestyle perspective. We should also ask the question: Is there an adaptive response to modest stress? Regarding development of a cancer-specific translational toxicology therapeutic portfolio; we note that there are biological concepts regarding adaptive responses to modest stressors (adaptive stressors) in contrast to those stressors that exceed one or more bounds of tolerance within which an adaptive response might range.

Our goal is to provide a general overview on windows of susceptibility/responsivity, including maternal and fetal metabolic milieu, childhood cancers and therapies, and transitions into adulthood.

If there is a plausible public health basis to advocate for implementation of certain mitigative risk-reducing interventions, what are the essential ethical considerations to be made for protective “treatments” of the young for prevention of some remotely future disease (cancers) that the individual may or may not otherwise experience? In Chapter 19 we have delved into this and numerous other ethical issues facing the new field of translational toxicology.

In addressing chemical and metabolic exposures of concern, we agree that risks and benefits need to be considered. In this volume, we include natural and anthropogenic substances, both carcinogenic and anticarcinogenic, in the diet with commentary regarding both the good and the bad potential effects of natural chemicals and the evidence supporting each. We note, particularly, the childhood cancers and therapies for those cancers that need to be addressed. Regarding an important window of susceptibility or responsivity, the peripubertal interval and the well-documented effect of early onset of menarche or breast cancer risk serve as good illustrations that will be discussed.

We note that any number of exposures could have an impact on the risk of cancer occurrence (as well as other diseases), and its indolent or aggressive behavior and progression over time. Chapters 5–8 are devoted to such exposures.

Environmental chemicals and drugs are a source of major concern in human exposure scenarios. We are exposed daily to low levels of literally thousands of industrial and household chemicals in our indoor and outdoor environments. For the most part, these represent involuntary exposures; however, we voluntarily expose ourselves to known human carcinogens in consuming alcoholic beverages and tobacco products. Not only do we expose ourselves, but also our children and even our grandchildren.

We briefly consider smoking relative to transgenerational cancer and other disorders. Thus, Dougan et al. [17] have studied grandmaternal smoking during pregnancy and its possible association with overweight status in adolescence. After adjusting for covariates, their findings suggest that the association between maternal smoking and offspring obesity may not persist beyond the first generation. However, grandpaternal smoking may affect the overweight status of the granddaughter, likely through the association between grandpaternal smoking and maternal smoking.

Pagani et al. [18] examined the reported behavioral habits of 2055 families by sifting through data from the Quebec Longitudinal Study of Child Development. The investigators looked particularly at levels of household tobacco smoke exposure when their child was between the ages of 1 and 7. They then attempted to ascertain any possible correlations between the level of smoking and measurements of the child's waist circumference and body mass index (BMI) at age 10. Higher amounts of both are known to predict a higher risk of gaining excess weight and developing metabolic disorders, such as diabetes, later on in adulthood.

“By the age of 10, those children who had been intermittently or continuously exposed to tobacco smoke were likely to have waists that were up to three-fifths of an inch wider than their peers. And their BMI scores were likely to be between 0.48 and 0.81 points higher,” stated lead author Dr. Linda Pagani, of the University of Montreal, in a press release. “This prospective association is almost as large as the influence of smoking while pregnant. The researchers noted that only occasional smoking exposure was independently associated with excess weight, after controlling for factors like their parent's mental health or income, with a 43 percent greater chance of a child becoming obese or overweight in such a household [18].”

For certain other exposures, the case for transmission of cancer risk to future generations, via both genetic and epigenetic mechanisms, is much stronger. Thus, in a study by Peters et al. on parental exposure to solvents and subsequent brain tumors in their children, parents of 306 cases and 950 controls completed detailed occupational histories. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for both maternal and paternal exposure to benzene, other aromatics, aliphatics, and chlorinated solvents in key time periods relative to the birth of their child. Adjustments were made for matching variables, including child's age, sex and state of residence, level of parental education, and occupational exposure to diesel exhaust. Their results demonstrated an increased risk of childhood brain tumors (CBT) with maternal occupational exposures to chlorinated solvents (OR = 8.59, 95% CI 0.94–78.9) any time before birth. Paternal exposure to solvents in the year before conception was also associated with an increased CBT risk mainly attributable to exposure to aromatic solvents: OR = 2.72 (95% CI 0.94–7.86) for benzene and OR = 1.76 (95% CI 1.10–2.82) for other aromatics [19].

The International Agency for Research on Cancer (IARC) has classified 118 agents as known human carcinogens (http://monographs.iarc.fr/ENG/Classification/). IARC considers an additional 75 agents as probable human carcinogens and another 288 agents as possible human carcinogens. Some of these are actually complex mixture of agents. Typically, in order to delineate the relative contribution of its chemical constituents, a mixture must be separated and chemically characterized. Two of the more pervasive complex mixtures of mutagens and carcinogens are combustion emissions and tobacco smoke (including direct, side stream, and environmental exposures).

Combustion emissions resulting from the burning of fossil fuels, in generating electricity, in heating our homes, or in powering our vehicles, represent a substantial contribution to the total human environmental exposure. These emissions include both particulates and products of incomplete combustion that represent the original starting materials (e.g., coal and crude oil). Their combustion yields carbon, sulfur, lead, mercury, and other elements. Fossil fuels can be refined to reduce unwanted constituents, and this has been important in the development of cleaner industries and engine technologies. Even so, oxidized sulfur and nitrogen, elemental products, and volatile organic carbon products (VOCs) are mutagenic, carcinogenic, and otherwise hazardous to human health.

Tobacco smoke (even tobacco vapor) and all tobacco products are human carcinogens. Volatile vapors, nonvolatile compounds, and fine particles are deposited directly into the airways and the pulmonary alveoli. The Food and Drug Administration (FDA) has listed 93 harmful and potentially harmful constituents (HPHCs) of tobacco products and tobacco smoke (Federal Register/Vol. 77, No. 64/Tuesday, April 3, 2012). These constituents account for much of the carcinogenicity and toxicity that is observed in smokers. Other risk factors associated with smoking include hypertension, stroke, atherosclerosis, and myocardial infarction. Smoking also affects reproductive health, causing delay in conception, low birth weight, and advanced menopause.

In addition to xenobiotic chemicals and drugs, human exposures also include both natural and synthetic substances as well as basic nutrition and supplements. For example, the introduction of industrial farming practices in the United States to meet consumer and processed food product requirements for low cost food has come about with significant problems of microbial contamination (from feces) and antibiotic resistance that have not been encountered previously on such a large scale. Thus, infectious exposures and food safety issues are important categories of concern for human exposure, particularly in children who can be frequent consumers, especially of fast foods containing highly processed meats.

Similarly, excessive exposures to the physical agents in the environment, including sunlight, noise pollution, nonionizing radiation, radon gas, and diagnostic medical radiation can be of concern with regard to cancer etiology. Social factors must also be addressed and have been examined more frequently with the evolution of new knowledge in the field of epigenetics, as will be discussed in Chapter 11.

We suggest as an organizing principle, taking a pan-life span view of cancer and to view what causes and prevents cancer in a cumulative incremental way (see Figure 1.1).

Figure 1.1 A pan-life span view of cancer risks and prevention.

This diagram aims to illustrate some of the various factors beginning prior to conception and extending across the subsequent life span that may drive lifetime risk of cancer(s) upward or downward. Some might plausibly have more impact during key developmental windows while others may be cumulative and rather more subchronic or chronic in terms of either risk or protection. Any number of factors could be important such as biological sex, ethnicity, fitness as an adolescent or teen, assumption of tobacco smoking, discontinuation of tobacco smoking, age at first birth, age of puberty, other behaviors/lifestyle choices. For each cancer or group of cancers, there would be sets of risk factors and risk modifiers (mitigation). Some of these factors are discussed in greater detail in Chapters 9 and 10.

What are some of the considerations that relate lifestyle choices to cancer? A meta-analysis was undertaken by Garcia-Jimenez et al. to examine the association between diabetes, obesity, and cancer. Their results indicated that the interplay between hyperglycemia, increase in adipose mass, and inflammation that appears with obesity is critical in both diabetes and cancer, suggesting that obesity may link diabetes and cancer. Indeed, epidemiological evidence positively associates obesity with many site-specific cancers. The associations are strong for endometrial and kidney cancer but weaker for bladder, prostate, and stomach cancers. It may be important to note that highly prevalent lung cancers are inversely associated with obesity. According to Garcia-Jimenez et al., type 2 diabetes (T2D) associates with most cancers that are linked to obesity. T2D represents >90% of diagnosed diabetes; studies that do not distinguish T1D from T2D follow a pattern similar to T2D. Significantly, most site-specific cancers that are positively associated with obesity show an even stronger association with T2D, suggesting that for those cancers T2D exhibits additional contributing factors [20].

What is the molecular basis of these kinds of associations? Genetically and biochemically there are many factors; however, one common denominator is Sirtuin 1 or SIRT1 (a member of the sirtuin family), which is a nicotinamide adenosine dinucleotide (NAD)-dependent deacetylase involved in removing acetyl groups from various proteins. SIRT1 performs a wide variety of additional functions in biological systems. Hubbard and Sinclair have reported that it deacetylates key histone residues involved in the regulation of transcription, including H3-K9, H4-K16, and H1-K26, as well as multiple nonhistone protein targets, including p53, forkhead box protein O1/3 (FOXO1/3), peroxisome proliferator-activated receptor gamma coactivator 1a (PGC-1a), and nuclear factor (NF)-kB. By targeting these proteins, SIRT1 is able to regulate numerous signaling pathways, including DNA repair and apoptosis, muscle and fat differentiation, neurogenesis, mitochondrial biogenesis, glucose and insulin homeostasis, hormone secretion, cell stress responses, and even circadian rhythm. The other sirtuins also play important roles in regulating mitochondrial reactions, glucose and insulin homeostasis, hepatic lipogenesis, DNA damage, telomere maintenance, inflammation, and the response to hypoxia [21].

Sun et al. have asserted that the dysregulation of SIRT1 can lead to ageing, diabetes, and cancer [22]. Using a ligand-based virtual screening of 1,444, 880 active compounds from Chinese herbs, they identified 12 compounds as inhibitors of SIRT1. Three compounds had high affinity for SIRT1 as estimated by a molecular docking software program. Rahman and Islam have recently reviewed the biological functions of SIRT1 in obesity-associated metabolic diseases, adipose tissue, and cancer. In addition, they discuss the involvement of this enzyme in aging, cellular senescence, cardiac aging and stress, prion-mediated neurodegeneration, inflammatory signaling in response to environmental stress, development, and placental cell survival [23].

Another sirtuin is Sir2 or SIRT2, and its homologs are class III histone deacetylases. They are distinguished from class I and class II deacetylases by their requirement for beta-nicotinamide adenine dinucleotide (NAD+) as a cosubstrate [21]. In mammals, there are seven sirtuin homologs (SIRT1–7). SIRT1, SIRT6, and SIRT7 localize primarily to the nucleus; SIRT3, SIRT4, and SIRT5 localize to mitochondria; and SIRT2 localizes to the cytosol [24]. Although sirtuins were originally described as deacetylases, it is now evident that they have broader activity [24]. In addition to deacetylation, SIRT5 possesses desuccinylase and demalonylase activities [24], SIRT4 and SIRT6 are mono-ADP ribosyltransferases [6,24], and SIRT6 can deacylate long-chain fatty acids [25]. Indeed, it has been shown that the ability to catalyze long-chain deacylation is a general feature of mammalian sirtuins, and that in the case of SIRT6, long-chain fatty acids can enhance deacetylase activity [26].

1.2.1 Mutagenic MOAs

The term “mode of action” (MOA) encompasses a sequence of key events and processes beginning with the interaction of a chemical with a cell and proceeding through functional and structural changes that result in cancer. It is well established that mutations in somatic cells play a key early role in cancer initiation and may affect other stages of the carcinogenic process. All cancer cells acquire multiple mutations during carcinogenesis; therefore, mutation induction or acquisition can be key events at some stage in all cancers. Two important considerations in assessing evidence for a mutagenic MOA are (1) when the mutation occurs among the events that lead to cancer and (2) whether the action of the carcinogen as a mutagen is a key event in its carcinogenic process [27].

Mutagenicity of a chemical or its metabolite is an obligatory early event in a mutagenic MOA for cancer. This is in contrast with other MOAs wherein mutations are acquired subsequent to other key events (e.g., cytotoxicity with regenerative proliferation). With a mutagenic MOA for carcinogenesis, the chemical is expected to interact with DNA early in the process and produce changes in the DNA that are heritable. That a chemical carcinogen can induce mutation in one of a number of mutation assays is not sufficient to conclude that it causes specific tumors by a mutagenic MOA or that mutation is the only key event in the pathway to tumor induction. It should be pointed out that the term “genotoxic” includes all effects on genetic information, whether or not the chemical interacts with the DNA. The term “mutagenic” implies interaction with DNA but not all carcinogenic chemicals that are capable of interacting with DNA will have a mutagenic MOA for cancer.

Yauk et al. reported the results of a 2013 International Working Group on Genotoxicity Testing [28]. This report will be discussed in detail in Chapter 2. The workshop key questions and outcomes were as follows: (1) Do genotoxicity and mutagenicity assays in somatic cells predict germ cell effects? Limited data suggest that somatic cell tests detect most germ cell mutagens, but there are strong concerns that dictate caution in drawing conclusions. (2) Should germ cell tests be done, and when? If there is evidence that a chemical or its metabolite(s) will not reach target germ cells or gonadal tissue, it is not necessary to conduct germ cell tests, notwithstanding somatic outcomes. However, it was recommended that negative somatic cell mutagens with clear evidence for gonadal exposure and evidence of toxicity in germ cells could be considered for germ cell mutagenicity testing. (3) What new assays should be implemented and how? There is an immediate need for research on the application of whole genome sequencing in heritable mutation analysis in humans and animals, and integration of germ cell assays with somatic cell genotoxicity tests. Focus should be on environmental exposures that can cause de novo mutations, particularly newly recognized types of genomic changes. Mutational events, which may occur by exposure of germ cells during embryonic development, should also be investigated. Finally, where there are indications of germ cell toxicity in repeat dose or reproductive toxicology tests, consideration should be given to leveraging those studies to inform of possible germ cell genotoxicity [28]. Additional information on mutagenic MOAs may be found in Chapter 2.

1.2.1.1 DNA Repair

DNA is subject to damage from environmental and dietary carcinogens, endogenous metabolites, certain anti-inflammatory drugs, and genotoxic chemo therapeutics. The prevention of mutations by DNA repair pathways led to an early appreciation of a role for repair in cancer avoidance. However, the broader role of the DNA damage response (DDR) emerged more slowly [29]. There are multiple DNA repair pathways, with subpathways providing lesion specificity. Nucleotide excision repair removes bulky DNA lesions; DNA nonhomologous end joining and homologous recombination repair DNA double-strand breaks; mismatch repair corrects mismatched base pairs; and base excision repair repairs damaged bases and links to single-strand break repair. Mutations in these pathways increase cancer susceptibility [29].

Cells respond to DNA damage by the activation of complex signaling networks that decide cell fate, promoting DNA repair and survival but also cell death. Whether it is to be cell survival or death depends on factors involved in DNA damage recognition, and DNA repair and damage tolerance, as well as on factors involved in the activation of apoptosis, necrosis, autophagy, and senescence. The pathways that dictate the fate of the cell also have key roles in cancer initiation and progression. Furthermore, they determine the outcome of cancer chemotherapy with genotoxic drugs. Understanding the molecular basis of these pathways is important not only for gaining insight into carcinogenesis, but also in prescribing successful cancer therapy [30].

DNA damage triggers multiple cellular responses: It activates cell cycle checkpoints that provide time for the cell to repair the damage before it interferes with the replication machinery. Checkpoints prevent progression from G1 to S phase and from G2 to M phase, and an intra-S phase checkpoint regulates fork progression or origin firing. Many tumors have inactivated checkpoint responses. If repair fails or is saturated, the remaining DNA damage impedes replication and transcription, and the activated DDR signal cell death via downstream pathways. Therefore, the ability of a cell to survive DNA damage is proportional to the extent of damage, the repair capacity of the cell, the level of cell proliferation, the status of p53 and key DDR proteins including ataxia-telangiectasia mutated (ATM), ATR, and DNA-PK, the effectiveness of activating DNA repair genes (which is dependent on epigenetic silencing and cellular transcription factors), and the execution of downstream cell death pathways.

There are two DNA damage response signaling pathways: ATM-dependent signaling is activated by double strand breaks; and ataxia telangiectasia and RAD3-related (ATR)-dependent signaling is activated by single-stranded regions of DNA. DDR signaling can activate apoptosis and checkpoint arrest, and can influence DNA repair. Mutations in ATM signaling components confer cancer susceptibility. However, ATR-deficient mice show reduced capacity for tumor formation [29]. Multiple processes function to maintain the accuracy of replication and enhance recovery from replication fork stalling or collapse. Homologous recombination has a key role, and genes involved in this process are commonly mutated in cancers. Several mechanisms prevent DNA rereplication that can cause aneuploidy and subsequently genomic instability. Cancer cells need to maintain telomere length to survive since shortened telomeres lead to senescence. Activation of telomerase or an alternative pathway to maintain telomere length is common in cancers.

DNA repair capacity differs greatly among cell types, with human embryonic stem cells repairing most DNA lesions more effectively than differentiated cell types [31], whereas monocytes and muscle cells are defective in base excision repair [32,33] and some cancers show upregulation of repair, for example, metastatic melanoma [34], or highly variable MGMT repair activity such as in gliomas [35,36]. In simple terms, a low level of DNA damage activates DNA repair (with upregulation of repair genes XPF, XPG, DDB2, XPC, XRCC1, and others), whereas with high levels of DNA damage, repair is saturated, and unrepaired DNA damage activates one of the death programmes, including apoptosis, regulated necrosis, and autophagy. Apoptosis represents a programmed cell death pathway that functions in some tissues during normal development but also prevents proliferation of damaged cells. Apoptosis can be p53 dependent or independent and p53 is commonly mutated in cancer [29]. It is not well understood how the cell switches between these pathways; however, it appears that the p53 phosphorylation status and antiapoptosis thresholds are key nodes in determining a cell's life or death following DNA damage. ATM and ATR seem to be the main decision makers, informing effectors such as p53 how to proceed. Increased drug resistance of tumors carrying mutations in ATM [37] illustrates the importance of ATM in initiating cell death pathways. Inactivation of p53 in cancer cells can lead to either drug sensitization or resistance, depending on the genotoxic agent employed.

Roos et al. [30] have suggested that targeting antiapoptosis proteins and pathways conceivably lowers the threshold for cell death for genotoxic and biological therapies. How specific DNA lesions activate and coordinate the complex interplay between survival and death is of fundamental importance for cancer therapy. The ultimate goal is to protect normal tissue during therapy with genotoxic anticancer drugs while sensitizing cancer cells to die. The protection of normal tissue has far-reaching implications for stem cells and for genome-compromised cells as the former have been shown to activate DNA damage-triggered apoptosis easily, and the elimination of the latter from the healthy cell population is a cancer prevention strategy.

1.2.2 Epigenetic MOAs